61
Austar Lifesciences Limited
6118.HK · HKSE
$0.71 -3.42% (-$0.03)
1M +1.39%
Market Cap ¥309.1M
P/E Ratio 9.14x
Div. Yield -
ROE 4.15%
Bulios Fair Price
$0.45
36.2% downside
Current Price
$0.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, 6118.HK is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
100 /100
Cheap EV/EBITDA 5.15x
P/S 0.20x
P/B 0.38x
Growth
1 /100
Declining Rev. growth 10.80%
Book val. growth 2.83%
EPS growth 27.05%
Profitability
28 /100
Weak Net margin 2.21%
Op. margin 3.54%
FCF margin 6.52%
Quality
22 /100
Poor ROE 4.15%
ROA 1.59%
Asset turnover 0.72x
Debt
77 /100
Low Current ratio 1.36x
Int. coverage 3.65x
Net debt/EBITDA 0.92x
Stability
57 /100
Moderate Rev. volatility 10.86%
EPS volatility 197.26%
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about 6118.HK
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Kwok Keung
Employees
1,468
Headquarters
Shanghai